Navigation Links
Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
Date:4/28/2009

Phase 3 IMPACT Trial Results to be presented during late-breaking session at AUA Annual Scientific Meeting

CHICAGO, April 28 /PRNewswire-USNewswire/ -- Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum. A special session for interested media will take place at 3:00 p.m. CT in the AUA Press Suite, room CC22 at the Hyatt Regency McCormick.

Compared to placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. Sipuleucel-T successfully exceeded the pre-specified level of statistical significance defined by the study's design and reduced the overall risk of death by 22.5 percent compared to placebo (p-value=0.032). More than 500 patients were enrolled in the IMPACT trial, a multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, androgen-independent prostate cancer. The primary endpoint was overall survival.

Researchers are encouraged by the findings, citing an impressive effect on long-term survival for patients, compared to placebo.

"The ability to boost survival for patients is the gold standard endpoint in prostate cancer clinical trials," said AUA spokesperson Ira D. Sharlip, MD. "The ability to give these patients both increased survival and possibly, improved quality of life, is very important."

Sipuleucel-T is an investigational therapy for men with androgen-independent prostate cancer. It is an active cellular immunotherapy designed to use live human cells to boost
'/>"/>

SOURCE American Urological Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... , August 19, 2014 Elbit ... EMITF ) announced today that Elbit Medical Technologies ... Company in which it holds approximately 86% of the ... Cell Ltd., in which Elbit Medical holds approximately 30.8% ... majority of Gamida Cell,s shareholders (including Elbit Medical), signed ...
(Date:8/18/2014)... , August 19, 2014 ... cell expansion technologies and therapeutic products, announced today that it ... Pharma AG  ( " Novartis " ... $35 million in Gamida Cell and in return will receive ... The option is exercisable for a limited period of time ...
(Date:8/18/2014)... YORK , Aug. 18, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Biopharmaceutical Markets ... be categorized into three types: chromatography, membranes/filters ... products is increasing and fueling growth of ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... Cempra Pharmaceuticals today announced results from its Phase ... tolerability of oral administration of our fourth generation ... with oral levofloxacin for the treatment of community-acquired ... CEM-101 demonstrated efficacy comparable to levofloxacin and a ...
... Sept. 15, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0240543/Global-Blood-Glucose-Test-Strips-Market-2010-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Test Strips market to grow at a ...
Cached Medicine Technology:Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 2Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 3Global Blood Glucose Test Strips Market 2010-2014 2
(Date:8/19/2014)... Horizon Blue Cross Blue Shield of New Jersey ... again teaming up during The Barclays at The Ridgewood ... Challenge, and Horizon BCBSNJ will be getting spectators into the ... their own. , Horizon BCBSNJ, the official health care sponsor ... donation to the New Jersey Golf Foundation, an organization that ...
(Date:8/19/2014)... NY (PRWEB) August 19, 2014 ... were named the winner of the 2014 Independent ... took home the first place position in “Product ... marketplace specially-formatted eyeliner, which also includes a lash ... black color, plus lash-boosting technology. , ...
(Date:8/19/2014)... August 19, 2014 Following the completion of ... Hyatt Tampa Bay is proud to debut the highly ... project included a full revamp of all public spaces to ... rooms and suites, an all-new dining experience at 1823 Kitchen ... lobby. , With the introduction of 1823 Kitchen and Bar, ...
(Date:8/19/2014)... Philadelphia, PA, August 19, 2014 Warfarin, the ... competition from new options in the anticoagulant drug ... study documents the rapid adoption of these novel ... NOACs accounted for 62% of all new anticoagulant ... drug costs. Findings are published in The ...
(Date:8/19/2014)... Title Boxing Club Cool Springs is now open. ... away prizes – including an entire year's membership. Sweepstakes ... and click on the “Hit It Hard” Sweepstakes. Once ... enters, you will receive an additional chance to win. ... take advantage of the “Pre-Opening Special” which Includes a ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:Title Boxing Club Cool Springs is Officially Open 2
... CBM ) reports fourth quarter and full year 2008 results ... , Sales increased 0.8% compared ... the impact of foreign currency. Reported sales declined by 6.6% ... Adjusted EBITDA (see attached table) was $10.7 ...
... New Product Development, Marketing and InnovationBEDFORD, Mass., Feb. ... and produced by Insulet Corporation (Nasdaq: ... for the prestigious 2009 Edison Best New Product ... accolades honoring excellence in new product development, marketing, ...
... to better diagnosis, treatment for heart patients , , WEDNESDAY, ... called contrast echocardiography had a significant impact on the ... a new study found. , Echocardiography bounces sound waves ... the moving heart. If that image isn,t clear enough, ...
... than $1000. , ... Eagan, MN (Vocus) February 11, 2009 -- Employees ... United Way of Northeastern Minnesota. A company cookbook was created and ... Iowa. More than 200 cookbooks were sold. , , , ...
... Doctors with Plastic Surgery Services of Fredericksburg ... area to offer LATISSE(TM), the new FDA-approved prescription ... darker, fuller and longer. LATISSE,s maker, Allergan, ... BOTOX(R) and Juvederm(TM). The active ingredient in LATISSE(TM) ...
... doctors at high-volume hospitals do best, study finds , , ... a person surviving a heart attack roughly double ... and facility experienced in the use of angioplasty and ... percutaneous coronary interevention (PCI), which uses angioplasty and a ...
Cached Medicine News:Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 2Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 3Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 4Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 5Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 6Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 7Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 8Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 9Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 10Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 11Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 12Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 13Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 14Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 15Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 2Health News:OmniPod(R) Insulin Management System Selected as a Finalist for the 2009 Edison Best New Product Awards(TM) 3Health News:Study Brings Value of Echocardiography Into Focus 2Health News:Company Cookbook Proceeds to Benefit United Way of Northeastern Minnesota 2Health News:Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg 2Health News:Experience Brings Better Angioplasty Outcomes 2
... Based on decades of experience, the SSD-1000 ... ultrasound system. It uses our advanced technologies ... experience. Using the same technology as our ... imaging capabilities in a compact and mobile ...
... Using pulsed radiofrequncy current, ... system quickly heats and ablates ... it in minimal time., RF ... in open surgery, percutaneously, or ...
... a biologically based adhesive supplied as ... consisting of a liquid substrate and ... internal bleeding. When combined ... to a prepared wound and tenaciously ...
... (Human) achieves a secure clot, targeted to ... for hemostasis is needed, when control of ... ligature, and cautery, is ineffective or impractical., ... formulation of human Biologically Active Component (BAC) ...
Medicine Products: